PER-022-02Completed未知
INTERNATIONAL STUDY, MULTICENTRIC, STRATIFIED, RANDOMIZED, DOUBLE-BLIND, WITH PLACEBO OVERLOAD, IN PARALLEL GROUPS, DURING 52 WEEKS OF GASTROINTESTINAL CLINICAL SECURITY, TO DEMONSTRATE THAT COX189 (400 MG / DAY OD) REDUCES THE RISK OF DISREGARDING COMPLICATED ULCERS COMPARING WITH NSAIDS (NAPROXENO 500 MG, BID AND IBUPROPHENE 800MG.ID) IN PATIENTS WITH OSTEOARTHRITIS, COX STUDY 1189 TARGET PART II
OVARTIS BIOSCIENSES PERU S.A.,0 sites0 target enrollmentStarted: February 28, 2002Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •*Pacientes ambulatorios, mujeres u hombres que cooperen, de 50 años de edad o mas.
- •*Pacientes con osteoartritis primaria con sintomas desde hace por lo menos 3 meses (el diagnostico puede efectuarse en la evaluacion). En cadera, rodilla o mano, de acuerdo a los criterios ACR
Exclusion Criteria
- •* Patients with rheumatoid arthritis who suffer from adult juvenile chronic arthritis.
- •* Patient with secondary osteoarthritis with history and / or any evidence in the joint, fixed as a potential target, of the following diseases: septic arthritis, inflammatory joint disease, gout, recurrent episodes of pseudogout, disease
- •Paget bone, fracture, oochronosis, acromegaly, hemochromatosis, Wilson´s disease, primary osteochondromatosis, hereditary disease (eg hypermobility), mutations of the collagen gene.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Ensayo multicéntrico, internacional, prospectivo, aleatorizado, doble ciego y con doble simulación que compara la seguridad y eficacia de la administración secuencial (intravenosa/ oral) de moxifloxacino 400 mg una vez al día con la administración de piperacilina/tazobactam 4,0/0,5 g por vía intravenosa cada 8 horas seguida de amoxicilina/ácido clavulánico comprimidos 875/125 mg por vía oral cada 12 horas para el tratamiento de pacientes con infecciones complicadas de la piel y los tejidos blandos (Estudio RELIEF) - RELIEFEUCTR2006-001599-18-ESBayer HealthCare AG804
Completed
Not Applicable
INTERNATIONAL MULTICENTER STUDY, DOUBLE-BLIND, RANDOMIZED, PHASE III OF SATRAPLATIN PLUSBO PLUSBO OR PREDNISONE PLUSBO IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER PREVIOUSLY TREATED WITH A REGIME OF CYTOXIC CHEMOTHERAPY GPC SAT3-03-01-C61 Malignant neoplasm of prostateMalignant neoplasm of prostateC61PER-001-04GPC BIOTECH INC.,
Active, not recruiting
Not Applicable
An international multi-centre one-year trial of effects and side-effects of CRD007 tablets for treatment of aneurysm (dilation) of the aorta (the largest artery in the body) in the abdominal cavity.Abdominal aortic aneurysm (AAA) is a dilatation of the aorta as it passes through theabdomen, defined as a dilatation of the infra-renal aorta to a diameter of 30 mm. AAA isgenerally asymptomatic and the greatest concern is the risk of rupture, which causes severepain, massive internal hemorrhage, and, without prompt treatment, death.MedDRA version: 13.1Level: LLTClassification code 10000054Term: Abdominal aortic aneurysmSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-000285-35-GBCardoz AB300
Active, not recruiting
Not Applicable
An international multi-centre one-year trial of effects and side-effects of CRD007 tablets for treatment of aneurysm (dilation) of the aorta (the largest artery in the body) in the abdominal cavity.Abdominal aortic aneurysm (AAA) is a dilatation of the aorta as it passes through theabdomen, defined as a dilatation of the infra-renal aorta to a diameter of 30 mm. AAA isgenerally asymptomatic and the greatest concern is the risk of rupture, which causes severepain, massive internal hemorrhage, and, without prompt treatment, death.MedDRA version: 14.1Level: LLTClassification code 10000054Term: Abdominal aortic aneurysmSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-000285-35-SECardoz AB300
Active, not recruiting
Not Applicable
An international multi-centre one-year trial of effects and side-effects of CRD007 tablets for treatment of aneurysm (dilation) of the aorta (the largest artery in the body) in the abdominal cavity.Abdominal aortic aneurysm (AAA) is a dilatation of the aorta as it passes through theabdomen, defined as a dilatation of the infra-renal aorta to a diameter of 30 mm. AAA isgenerally asymptomatic and the greatest concern is the risk of rupture, which causes severepain, massive internal hemorrhage, and, without prompt treatment, death.MedDRA version: 14.1Level: LLTClassification code 10000054Term: Abdominal aortic aneurysmSystem Organ Class: 10047065 - Vascular disordersEUCTR2011-000285-35-DKCardoz AB300